The Strategic National Stockpile 2012: Updates and Overview
(LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-101-L04-P & 112-000-12-801-L04-T, 1.3 contact hours
Gregory Pratt, R.Ph., emergency preparedness coordinator, Michigan Pharmacists Association, Lansing, Mich.
At the end of this presentation, participants should be able to state the purpose and goals of the strategic national stockpile (SNS) program; describe the most current process for a facility when requesting and receiving medical countermeasures from the SNS; and discuss the coordination of SNS and other cache requests during the presentation of a possible developing scenario.

The Medicare Drug Program in 2012 (Ambassador Ballroom 2, Level 3)
Knowledge-type Activity
112-000-12-102-L04-P & 112-000-12-802-L04-T, 1.3 contact hours
Todd Stankewicz, R.Ph., regional pharmacist, Centers for Medicare & Medicaid Services, Chicago, Ill.
At the end of this presentation, participants should be able to define the enhancements occurring in 2012 with the Medicare prescription drug benefit; explain how the coverage gap discount program will affect Medicare beneficiaries; identify specific categories of drugs which may qualify for coverage under Parts A, B and D; and recognize the resources available to pharmacists to facilitate understanding of the Medicare Part D drug benefit.

Overview of Oncolytic Agents (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-103-L01-P & 112-000-12-803-L01-T, 1.0 contact hour
Claire Saadeh, Pharm.D., professor of pharmacy practice, Ferris State University College of Pharmacy, DeWitt, Mich.
At the end of this presentation, participants should be able to summarize the place in therapy of the oral oncolytic agents reviewed; discuss the commonly encountered side effects associated with the oral oncolytic agents; and outline a patient counseling plan for any given oral oncolytic agent.

The Pharmacist’s Role in Management of Acute Tooth Pain:
The Common Tooth Ache, Diagnosis and Treatment
(Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-104-L01-P & 112-000-12-804-L01-T, 1.0 contact hour
William P. Maher, R.Ph., DDS, diplomate, American Board of Endodontics, Troy, Mich.
At the end of this presentation, participants should be able to discuss the cause and treatment of tooth ache pain; identify the possible treatment options available to the pharmacist in providing short-term relief; and review use and abuse of nitrous oxide. (This program meets requirements for obtaining pain management continuing education credit for pharmacists.)

From Good to Great Community Pharmacy Practice:
The Utilization of Students and Residents
(Ambassador Ballroom 3, Level 3)
112-000-12-105-L04-P, 1.3 contact hours
Knowledge-type activity
Susan DeVuyst-Miller, Pharm.D., community practice resident, Meijer Pharmacy, Grand Rapids, Mich.; Lisa M. Meny, Pharm.D., assistant professor of pharmacy practice, Ferris State University College of Pharmacy, Grand Rapids, Mich.; and Lisa A. Ribecky, Pharm.D., pharmacy resident, Meijer Pharmacy, Muskegon, Mich.
At the end of this presentation, participants should be able to determine the role of student pharmacists in advancing community practice; describe how student pharmacists could be used effectively in your pharmacy practice; and design a plan for improving the utilization of students in your pharmacy practice.
Sponsored by Michigan Colleges of Pharmacy Experiential Programs (McPEP) Committee that is comprised of individuals from Ferris State University, Michigan Pharmacists Association, University of Michigan and Wayne State University

Clinical Pearls: Pediatrics, Pulmonary Arterial
Hypertension, Refeeding Syndrome
(Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-106-L04-P & 112-000-12-806-L04-T, 1.3 contact hours

• Medication Management of Pulmonary Arterial Hypertension Medications that Demand R-E-S-P-E-C-T
  Jennifer L. Priziola, Pharm.D., critical care pharmacist, Beaumont Health System, Troy, Mich.
  At the end of this presentation, participants should be able to recognize parenteral prostacyclin therapy utilized in managing PAH; describe the safety considerations of parenteral prostacyclin therapy; and discuss potential opportunities for pharmacist’s involvement in ensuring safe medication practices for parenteral prostacyclin therapy.
• What You Need to Know About Acetaminophen and Children: Product Updates and Current Controversy
  Elizabeth J. Beckman, Pharm.D., clinical pharmacy specialist, pediatric critical care, C.S. Mott Children’s and Women’s Hospital, University of Michigan Hospital and Health Systems, Ann Arbor, Mich.
  At the end of this presentation, participants should be able to review the recent acetaminophen product labeling and oral suspension concentration changes; recognize the controversy surrounding prenatal acetaminophen exposure and acetaminophen use in children and the risk of asthma; and describe the advantages and disadvantages associated with acetaminophen administration at the time of immunization.
• Food for Thought: Refeeding Syndrome Clinical Pearls
  Michael D. Kraft, Pharm.D., clinical assistant professor of pharmacy, University of Michigan College of Pharmacy, Ypsilanti, Mich.
  At the end of this presentation, participants should be able to identify patients at risk for refeeding syndrome; describe measures to prevent refeeding syndrome in adult patients requiring nutrition support therapy; and describe measures to treat refeeding syndrome in adult patients receiving nutrition support therapy.

A Collaborative Approach to Ensure Optimal Management of Chronic Diseases (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-107-L04-P & 112-000-12-807-L04-T, 1.3 contact hours
Michael J. Bouthillier, Pharm.D., interim assistant dean, Ferris State University College of Pharmacy, Walker, Mich.; John P. Jameson, professor, Ferris State University College of Pharmacy, Rockford, Mich.; and Frederick E. Schmidt, R.Ph., Cherry Street Health Center, Grandville, Mich.
At the end of this presentation, participants should be able to identify how a national collaborative approach is focusing on clinical pharmacy services to mitigate adverse drug events and produce positive patient outcomes; explain pharmacy’s role in the integrated care model; and explain the role of building relationships with patients and providers within a patient-centered medical home environment.

Blue Cross Blue Shield of Michigan/Blue Care Network (BCBSM/BCN) Pharmacy Audit Update 2012
(Ambassador Ballroom 1, Level 3)
Knowledge-type Activity
112-000-12-108-L04-P & 112-000-12-808-L04-T, 1.3 contact hours
David Keener, R.Ph., manager, utilization review, Blue Cross Blue Shield of Michigan, Ferndale, Mich.
At the end of this presentation, participants should be able to discuss current audit findings; explain the contract requirements for Blue Cross Blue Shield of Michigan (BCBSM)/Blue Care Network (BCN) audits; explain how to correctly submit compound claims; and describe what changes have occurred in 2012 for BCBSM/BCN audits.

New Drug Update Part 1: Community Pharmacy Focus
(Ambassador Ballroom 2, Level 3)
Knowledge-type Activity
112-000-12-109-L01-P & 112-000-12-809-L01-T, 1.3 contact hours
Jacqueline Morse, Pharm.D., assistant professor of pharmacy practice, Ferris State University College of Pharmacy, Grand Rapids, Mich.
At the end of this presentation, participants should be able to identify medications that were Food and Drug Administration-approved within the last 12 months; describe indications, doses and formulations, adverse effects and drug interactions of recently approved medications; and discuss pertinent counseling points and monitoring parameters related to recently approved medications.

Using Antimicrobials Responsibly: Right Drug,
Right Dose, Right Duration (Marquette A-B, Level 5)
Knowledge-type Activity
112-000-12-110-L01-P & 112-000-12-810-L01-T, 1.3 contact hours
Megan Fletcher, Pharm.D., clinical coordinator, Mercy Hospital, Grayling, Mich.; Ryan Mynatt, Pharm.D., clinical pharmacist specialist of infectious diseases, Detroit Receiving Hospital and University Health Center, Detroit, Mich.; and Donald Scott, Pharm.D., clinical specialist of infectious diseases, Spectrum Health Hospitals, Butterworth, Grand Rapids, Mich.
At the end of this presentation, participants should be able to describe the three goals of an antimicrobial stewardship program; list desirable hospital personnel to be involved in an antimicrobial stewardship program; and describe methods used to improve antimicrobial use in the hospital.

Guidelines are Like a GPS: If You Don’t Follow Them,
You are Lost – A Pro/Con Debate (LaSalle A-B, Level 5)
Application-type Activity
112-000-12-111-L01-P & 112-000-12-811-L01-T, 1.3 contact hours
John P. Jameson, Pharm.D., professor, Ferris State University College of Pharmacy, Rockford, Mich.; and Dean A. Van Loo, Pharm.D., associate professor, Ferris State University College of Pharmacy and Bronson Methodist Hospital, Kalamazoo, Mich.
At the end of this presentation, participants should be able to list the limitations of guidelines when applying them to a particular patient case; determine whether a particular study should be applied or not, given a patient case; and determine when the evidence is inappropriate to make treatment decisions, given a particular disease state.

Gaining Operational Efficiencies in Your Pharmacy
(Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-154-L04-P & 112-000-12-854-L04-T, 1.3 contact hours
Jennifer Zilka, director of business coaching, AmerisourceBergen Drug Company, St. Paul, Minn.
At the end of this presentation, participants should be able to explain how to maximize reimbursement and increase overall profitability; discuss how to optimize your inventory to ensure you have the right product at the right time and the long-term financial benefits of maintaining appropriate inventory levels; and explain how to obtain appropriate staffing levels for your pharmacy.

Reinventing State Government:
2011 Observations and Looking Ahead to 2012
(Ambassador Ballroom 1, Level 3)
Knowledge-type Activity
112-000-12-112-L03-P & 112-000-12-812-L03-T, 1.3 contact hours
Rep. Lesia Liss (D-Warren), Michigan House of Representatives, Lansing, Mich.; Rep. Gail Haines (R-Lake Angelus), Michigan House of Representatives, Lansing, Mich.; Sen. Jim Marleau (R-Lake Orion), Michigan Senate, Lansing, Mich.; Sen. Rebekah Warren (D-Ann Arbor), Michigan Senate, Lansing, Mich.; and Rep. Jimmy Womack (D-Detroit), Michigan House of Representatives, Lansing, Mich.
At the end of this presentation, participants should be able to identify issues being considered by the Michigan Legislature that may impact pharmacy; identify the need for pharmacists and pharmacy technicians to become involved in the legislative process; and explain the impact of the state budget upon health care programs. (This program meets pharmacy law requirements for certified pharmacy technicians.)

New Drug Update Part 2: The Rest (Ambassador Ballroom 2, Level 3)
Knowledge-type Activity
112-000-12-113-L01-P & 112-000-12-813-L01-T, 1.3 contact hours
H. Stephen Lee, Pharm.D., associate professor of pharmacy practice, Ferris State University College of Pharmacy, Grand Rapids, Mich.
At the end of this presentation, participants should be able to identify medications that were Food and Drug Administration-approved within the last 12 months; describe indications, doses and formulations, adverse effects and drug interactions of recently approved medications; and discuss pertinent counseling points and monitoring parameters related to recently approved medications.

The Pharmacy Model Initiative in Michigan
(Ambassador Ballroom 3, Level 3)
112-000-12-153-L04-P & 112-000-12-853-L04-P, 1.3 contact hours
Knowledge-type activity
Ryan J. Bickel, Pharm.D., clinical pharmacy specialist, Borgess Medical Center, Kalamazoo, Mich.; Richard L. Lucarotti, Pharm.D., professor, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Beverly Hills, Mich.; and Kathleen S. Pawlicki, Pharm.D., administrative director, professional services, William Beaumont Hospital, Royal Oak, Mich.
At the end of this presentation, participants should be able to state the purpose of the American Society of Health-System Pharmacists Pharmacy Practice Model Initiative; list the six areas of recommendations from the Pharmacy Practice Model Initiative of Michigan (PPMI²) Conference; state the steps taken by the Michigan Society of Health-System Pharmacists to implement the recommendations from the PPMI² Conference; and list the focus of recommendations related to education emanating from the PPMI² Conference.
Sponsored by Michigan Colleges of Pharmacy Experiential Programs (McPEP) Committee that is comprised of individuals from Ferris State University, Michigan Pharmacists Association, University of Michigan and Wayne State University

Improving Individual Patient Care through
Engaging Communities in Partnerships to Reduce
Adverse Drug Events
(Marquette A-B, Level 5)
112-000-12-114-L04-P & 112-000-12-814-L04-T, 1.3 contact hours
Knowledge-type Activity
James C. Mitchiner, MD, medical director, MPRO, Farmington Hills, Mich.
At the end of this presentation, participants should be able to identify the Centers for Medicare and Medicaid Services’ (CMS) 10^th Scope of Work Care Transitions initiatives; describe the goals of CMS’ adverse drug event (ADE) initiative and Health Resources & Services Administration’s Patient Safety and Clinical Pharmacy Services Collaborative model to reduce and prevent ADEs in the high medication risk patient population; and define the role of clinical pharmacy services on the patient-centered, integrated health care team.

Peer Review and Incentivized Voluntary Error Reporting –
The Michigan System (LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-115-L04-P & 112-000-12-815-L04-T, 1.3 contact hours
Douglas A. Miller, Pharm.D., professor, department of pharmacy practice, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Mich.
At the end of this presentation, participants should be able to describe incentivized voluntary reporting as it relates to dispensing errors and the peer review process that has been established in Michigan; discuss the benefits of the Michigan system of voluntary error reporting as they relate to the pharmacist, the pharmacy, the profession and the public; and outline the steps a pharmacist must follow to participate in the Michigan incentivized voluntary reporting system.

How Pharmacies Fit Into the Patient-Centered Medical Home
(Brule A-B, Level 5)
Knowledge-type Activity
112-000-12-116-L04-P & 112-000-12-816-L04-T, 1.3 contact hours
Helen Berlie, Pharm.D., clinical assistant professor, Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, and ambulatory care specialist, Health Centers Detroit, Detroit, Mich.; Heather L. Christensen, Pharm.D., director of pharmacy services, Spectrum Health United Memorial, Greenville, Mich.; Erica R. Clark, Pharm.D., senior clinical pharmacy manager, Priority Health, Grand Rapids, Mich.; and Vanita Pindolia, Pharm.D., vice president, ambulatory clinical pharmacy programs, Henry Ford Health System and Health Alliance Plans of Michigan, Canton, Mich.
At the end of this presentation, participants should be able to describe the patient-centered medical home (PCMH) model; identify opportunities within the practice sites for pharmacist involvement and interaction; and discuss reimbursement strategies for practicing within the PCMH. Participants should also be able to identify resources and references to utilize for PCMH practices; and describe the rules and regulations that pertain to practice in the PCMH.

Safe Medical Disposal: Proposed Rules
and Guidelines (Ambassador Ballroom 1, Level 3)
Knowledge-type Activity
112-000-12-117-L03-P & 112-000-12-817-L03-T, 1.3 contact hours
Joseph Rannazzisi, deputy assistant administrator, Office of Diversion Control, U.S. Drug Enforcement Administration, Arlington, Va.
At the end of this presentation, participants should be able to review historical and recent pharmaceutical abuse trends in the United States; explain the Federal Controlled Substances Act and its impending regulations as it relates to controlled substance collection and disposal; discuss collection and disposal methods, programs and initiatives prior to the passage of the Secure and Responsible Drug Disposal Act of 2012; and explain the mandates and regulatory authorities granted to the Drug Enforcement Administration under the Secure and Responsible Drug Disposal Act of 2010. (This program meets pharmacy law requirements for certified pharmacy technicians.)

Drat! What Do I Do Now With These HIV Prescriptions? (Brule A-B, Level 5)
Application-type Activity
112-000-12-118-L01-P & 112-000-12-818-L01-T, 1.3 contact hours
Jean C. Lee, Pharm.D., AAHIVE, clinical pharmacist of HIV medicine, St. Mary’s Health Care, Grand Rapids, Mich.
At the end of this presentation, participants should be able to identify HIV antiretroviral agents by class, generic name, brand name and co-formulations; provide a basic patient medication education regarding dosing of combination therapy; state the importance of food requirements and restrictions with antiretrovirals; and identify medications that must be dispensed with ritonavir. (Seating limited to the first 30 participants.)

Continuous Quality Improvement — A Way to Enhance Patient Safety
(LaSalle A-B, Level 5)
Knowledge-type Activity
112-000-12-119-L04-P & 112-000-12-819-L04-T, 1.3 contact hours
Heather Meyers, director of business development, Pharmacy Services Inc., Lansing, Mich.
At the end of this presentation, participants should be able to identify the importance of quality improvement in health care; differentiate between types of quality-related events; define patient safety organization; define elements of a continuous quality improvement program; and identify ways to implement continuous quality improvement processes in your pharmacy practice.

Improving Patient Adherence: Using a Specific Adherence Tool for Success
(Cadillac A-B, Level 5)
Knowledge-type Activity
112-000-12-120-L04-P & 112-000-12-820-L04-T, 1.3 contact hours
Colleen McHorney, senior director, United States Outcomes Research, Merck & Company, Upper Gwynedd, Penn.; and panelists to be determined
At the end of this presentation, participants should be able to define adherence problems and their impact on the practice of pharmacy; discuss research findings related to patient beliefs and behaviors; identify at-risk patients and recall how to better communicate with them; and list practical tools that will help improve treatment outcomes for patients. The Adherence Estimator™ tool will be available at no cost to the first 50 attendees that request it.

Clinical Updates in Pain Management
(Ambassador Ballroom 1, Level 3)
Knowledge-type Activity
112-000-12-121-L01-P & 112-000-12-821-L01-T, 1.3 contact hours
Claire Saadeh, Pharm.D., professor of pharmacy practice, Ferris State University College of Pharmacy, DeWitt, Mich.
At the end of this presentation, participants should be able to describe the state of Michigan and national initiatives addressing the efforts to remove barriers to effective pain management; summarize the place in therapy of recent Food and Drug Administration-approved medications for managing pain; and discuss recent recommendations to enhance patient safety surrounding analgesic therapies. (This program meets requirements for obtaining pain management continuing education credit for pharmacists.)

Opening Session:
Building the Next Generation of Health Care
(Ambassador Ballrooms 2-3, Level 3)
Knowledge-type Activity
112-000-12-122-L04-P & 112-000-12-822-L04-T,
1.0 contact hour
B. Douglas Hoey, R.Ph., executive vice president and chief executive officer, National Community Pharmacists Association, Alexandria, Va.
At the end of this presentation, participants should be able to provide an overview of the community pharmacy marketplace, including demographic, economic and patient care services offered. Participants should also be able to describe the value of individualized responsibility for pharmacists to use political advocacy to positively influence their profession and patients in a meaningful way; discuss why pharmacists must “own” medication adherence and tactics they can employ to effect this outcome; and identify why interoperable technology is vital to enhancing pharmacist’s recognized value to the health care system.